Thomssen Christoph, Lüftner Diana, Untch Michael, Haidinger Renate, Würstlein Rachel, Harbeck Nadia, Augustin Doris, Briest Susanne, Ettl Johannes, Fasching Peter A, Förster Frank, Kurbacher Christian M, Lück Hans-Joachim, Marschner Norbert, Müller Lothar, Müller Volkmar, Perlova-Griff Lidia, Radke Isabel, Ruckhäberle Eugen, Scheffen Iris, Schumacher-Wulf Eva, Schwoerer Moritz, Steinfeld-Birg Dieter, Ziegler-Löhr Katja
Klinik und Poliklinik für Gynäkologie, Martin-Luther-Universität Halle-Wittenberg, Halle an der Saale, Germany.
Medical Department of Hematology, Oncology, and Tumor Immunology, Charité Berlin, Campus Benjamin Franklin, Berlin, Germany.
Breast Care (Basel). 2020 Feb;15(1):82-95. doi: 10.1159/000505957. Epub 2020 Feb 10.
The 5th International Consensus Conference for Advanced Breast Cancer (ABC5) took place on November 14-16, 2019, in Lisbon, Portugal. Its aim is to standardize the treatment of advanced breast cancer based on the available evidence and to ensure that all breast cancer patients worldwide receive adequate treatment and access to new therapies. This year, the conference focused on developments and study results in the treatment of patients with hormone receptor-positive/HER2-negative breast cancer as well as precision medicine. As in previous years, patient advocates from around the world were integrated into the ABC conference and had seats on the ABC consensus panel. In the present paper, a working group of German breast cancer experts comments on the results of the on-site ABC5 consensus votes by ABC panelists regarding their applicability for routine treatment in Germany. These comments take the recommendations of the Breast Committee of the Gynecological Oncology Working Group (; AGO) into account. The report and assessment presented here pertain to the preliminary results of the ABC5 consensus. The final version of the statements will be published in and .
第五届晚期乳腺癌国际共识会议（ABC5）于2019年11月14日至16日在葡萄牙里斯本举行。其目的是根据现有证据规范晚期乳腺癌的治疗，并确保全球所有乳腺癌患者都能获得充分治疗并使用新疗法。今年，会议聚焦于激素受体阳性/人表皮生长因子受体2阴性乳腺癌患者治疗的进展和研究结果以及精准医学。与往年一样，来自世界各地的患者倡导者融入了ABC会议，并在ABC共识小组中拥有席位。在本文中，一个德国乳腺癌专家工作小组对ABC小组专家关于其在德国常规治疗适用性的现场ABC5共识投票结果发表评论。这些评论考虑了妇科肿瘤学工作组（AGO）乳腺委员会的建议。此处呈现的报告和评估涉及ABC5共识的初步结果。声明的最终版本将发表于[具体刊物1]和[具体刊物2]。
